AstraZeneca sticks to H2 2015 timetable for new lung cancer pill

MADRID, Sept 27 (Reuters) - AstraZeneca said on Saturday it expected to file a new lung cancer pill for U.S. regulatory approval in the second half of 2015, potentially disappointing some investors who had hoped the drug might be ready faster.